1
. The first step in drug discovery is often a fast, cost-efficient assay, to 'screen' many compounds for 'hits' , or compounds that produce some enhanced or diminished signal for a targeted interaction. The second step is to submit these hits to a dose-response series of the first assay, seeking to prioritize the hits as leads for follow-up. The third step uses an independent molecular or cell-based assay to validate the prioritized compounds.
Use of flow cytometry in drug discovery screens
We have described previously methods that allow flow cytometers to be used in screening cells for molecules that regulate the binding of fluorescent ligands to their receptors on cells, as well as general principles for applying such screening systems in 96-and 384-well plates 2 . Briefly, to allow quick sampling from a multiwell plate to a cytometer, an autosampler is connected with flexible tubing and a peristaltic pump to a flow cytometer. When the autosampler probe is down in a well, 1-2 µl of suspension is drawn into it, and when the probe is up, an air bubble is drawn into it; as a result, a plate is read as a single time-based file of many suspensions of cells, each separated by air bubbles. This system for automated flow cytometry is named HyperCyt. The protocol described here assumes knowledge of the general principles of flow cytometry and HyperCyt (see ref. 2) , and is intended to extend the utility of HyperCyt to include the use of protein-coated beads in addition to cells, 384-well plates in addition to 96-well plates and fluorescent labeling of the beads to allow multiplexing. Once a series of related fluorescent assays have been developed and their limitations have been determined, a multiplex screen can be carried out.
Bcl-2 family proteins dimerize via their BH3 helices
The Bcl-2 protein was discovered during positional cloning of the t(14;18) chromosomal breakpoint in follicular lymphomas, in which the protein is overexpressed because of the proximity of the immunoglobulin heavy-chain gene enhancer on chromosome 14 (refs. 3-5) . This finding, coupled with the evidence that overexpression of Bcl-2 can inhibit the apoptotic form of programmed cell death, suggested that cancer can result from a lack of appropriate cell death, in addition to excess cell growth. The family is composed of both proapoptotic and antiapoptotic proteins, and now includes about nine core members that share several homology regions, as well as a larger number of diverse regulators that share only the BH3 domain, which is an amphipathic peptide of 16-20 amino acids 6 . The 3D structure of the Bcl-2 family protein Bcl-xL co-crystallized with the Bak BH3 peptide was reported in 1997 (ref. 7) , and it guides our thoughts about how these proteins multimerize, and about the conditions that cause or inhibit cell death. Briefly, overexpression or activation of proapoptotic family members increases cell death, whereas overexpression of antiapoptotic family members inhibits cell death by binding the activated BH3 helices 8, 9 . Chemical inhibitors of this binding have been identified by many approaches, and some of these are in clinical trials as candidate anticancer agents 10 .
Overview of the procedure
The apoptotic family member Bim has a BH3 peptide that binds to all six antiapoptotic family members, and we have used a fluoresceinated Bim BH3 peptide (F-Bim) in our screen. A schematic diagram of our strategy is shown (Fig. 1) . The six antiapoptotic family members (Bcl-xL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1) are all expressed separately as glutathione-S-transferase (GST) fusion proteins in bacteria, affinity purified, cleared of glutathione (GSH) and mixed individually with six GSH bead sets. Each set of beads is labeled with a defined quantity of a red fluorophore, which provides a distinct intensity of red fluorescence (please see REAGENTS and Fig. 1 for further description of these beads). The coated beads are washed, mixed together and incubated with potential inhibitors plus F-Bim in a plate with end-over-end (inverted to upright) rotation for 1 h at Simultaneous in vitro molecular screening of protein-peptide interactions by flow cytometry, using six Bcl-2 family proteins as examples 4 °C. The plate is sampled with HyperCyt and the resulting series of bubble-separated bead clusters is measured by flow cytometry. The flow cytometry data are acquired as a list mode file, which provides the arrival time, forward scatter, side scatter and green and red fluorescence intensity of each particle. The file is analyzed and reduced in size subsequently with a specialized software (HyperCytDataAnalysis) that identifies the mean or median fluorescence for each colorcoded bead set and the number of bead events associated with each set for each well. To achieve this, the mixed bead sets are gated for singlet beads as shown (Fig. 1b) , then for each bead set as shown (Fig. 1c) , allowing, for example, the amount of green fluorescence on the beads in gate 3 to be identified as a measure of F-Bim binding to Bcl-xL. Uncoated GSH beads are also detected in the assay (gate 9) and serve as a measure of fluorescence background due to the binding of F-Bim directly to beads, or due to the scavenging of dissociated GST-Bcl-2 family proteins from the suspension with bound F-Bim. The HyperCyt analysis software also rapidly divides the file into 384 clusters of events (wells), records and calculates the desired measures of the data and exports these as an Excel .csv file. Assay-specific analysis spreadsheets are designed with macros (Microsoft Excel), into which the .csv file is placed; these assemble the desired statistics and graphs, and flag possible hits for each molecular library plate in a batch mode. Supplementary Method shows 384-well 'plate maps' for the screening assay and for 32 doseresponse series; Supplementary Data 1 (see also Supplementary Note 1) shows an analysis spreadsheet for the screening plate shown in Figure 2 ; and Supplementary Data 2 (see also Supplementary Note 2) shows an analysis spreadsheet for 32 compounds that had been identified as 'hits' , carried out as 32 dose-response series. Most importantly, the screening analysis spreadsheet computes the average negative control for a plate for each protein, determines whether the fluorescence signal is reduced by at least 40% for any compounds and flags those compounds. Because Excel does not have a robust analysis for dose-response curves, we have used the program Prism (GraphPad software) to analyze the dose-response data, and then import Prism's analysis of the dose responses in batch mode. These steps are currently in the process of being replaced by more automated processes. Most importantly, the dose-response analysis calculates whether the effector concentration for half-maximum response (EC 50 ) value is less than 10 µM for each protein; it also calculates whether the uninhibited signal is reduced by at least 40% for any compounds and then flags those compounds.
Validation of multiplexing using Bcl-2 family proteins
To validate our multiplex approach, we determined binding curves for all six proteins with the fluorescent peptide ( Fig. 3a) and competition curves for F-Bim, using a known inhibitor (ABT-737) of four of the six proteins (Fig. 3b) . The binding and inhibition constants obtained thus far agree with the literature, with due regard for differences in assay procedures 11 . We report here simultaneous measurements of six protein interactions of targets with a fluorescent peptide probe, which saves time and reagents by multiplexing, and allows compound selectivity to be observed in a single 10-µl well in the primary screen. We have used this approach to screen 194,920 compounds and have reported the results in PubMed: search PubChem BioAssay for Bcl-2; assay identification numbers (AID numbers) are 950 (Bcl-2), 951 (Bcl-B), 952 (Bcl-W), 1007 (Bcl-xL), 1008 (Bfl-1) and 1009 (Mcl-1). Limitations of the primary assay arise statistically from false positives and false negatives, as well as from compounds that are fluorescent or interfere with the recognition motif that attaches the protein target to microspheres. The potential for multiple activities within a single well reduces the statistical uncertainty associated with nonselective compounds. The use of a seventh, appropriately configured, control set of beads in each well may serve as a measure of compound fluorescence for the well.
Comparison of fluorescence polarization with flow cytometry for screening Several methodologies, including time-resolved fluorescence resonance energy transfer (TR-FRET, http://www.htrf.com/technology/ htrftheory/tr_basics/), AlphaScreen (http://www.perkinelmer.com/ Catalog/Category/ID/AlphaScreen%20Assays%20and%20Reagents) and fluorescence polarization are commonly used to detect the binding of a small fluorescent ligand to a protein, and in general these methods may be considered for conversion to a multiplex flow cytometric format 12 . In the case of TR-FRET and polarization, the target components would require assembly on beads. In the case of In a plot of forward scatter versus side scatter, a gate is drawn around the singlet beads (identified as the major light blue 'dot cloud' compared with buffer without any beads; doublets occur at slightly higher forward scatter and side scatter, and appear as dark blue dots in this figure) . (c) Gates are drawn around each bead set using their red fluorescence as shown. In our example, the beads in gate 3 were coated with Bcl-xL, and the amount of green fluorescence on them would be a measure of the F-Bim bound to Bcl-xL. FS, forward scatter; lin, linear; SS, side scatter; log, logarithm; FL 8, red fluorescence.
AlphaScreen, with the targeted components bridging two beads, one of the bead components is replaced by a fluorescent component. All of these methods can be highly automated, and they now have the potential to be carried out in 1,536-well plates.
It is informative to compare the bead-based assay described here with fluorescence polarization in solution. The fluorescence from the small ligand is less polarized when unbound and more polarized when bound to the large protein 13 . To obtain 50% of the maximal polarization change, and the most sensitive concentration for observing any change in polarization, the protein should be present at the dissociation constant (K d ) of the interaction. For screening, test compounds are also added: an inhibitor would decrease polarization, and an activator would increase polarization. For the six proteins tested here by HyperCyt, the fluorescent peptide had an average K d of 50 nM. Using these concepts, a fluorescence polarization assay might use 2 nM fluorescent ligand and 50 nM protein to obtain 50% of the maximal signal. To obtain 50% of the maximal signal on beads, the fluorescent ligand should be present at the K d of the interaction; therefore, this report uses 50 nM fluorescent ligand and 2 nM (or less, depending on bead and site density) protein. Flow cytometry thus has the potential to use the precious protein reagent efficiently. Moreover, flow cytometry is not affected by the limitation that arises as the fluorescent molecule increases in mass such that the difference between the polarization of the free and bound species decreases. In a flow cytometer, the beads are in a narrow stream of assay buffer in which the laser beam illuminates only a small volume of buffer surrounding the bead; the cytometer then records the fluorescence of the bead above the buffer fluorescence, allowing homogeneous, no-wash detection of bead fluorescence, typically up to at least a 100 nM fluorophore. Screening six proteins per well increases assay efficiency, decreases use of precious reagents, shows selectivity of the small molecule interaction if such exists and can include appropriate fluorescence control beads. Fluorescence polarization provides an advantage for a single assay, requiring one mix step and a plate reader, versus flow cytometry, which requires a bead-coating step, a mix step and HyperCyt plus a flow cytometer.
Using fusion proteins for multiplexed flow cytometric assays
A hallmark multiplexed assay with moderate throughput was previously described, in which 15 cytokines were detected simultaneously using a flow cytometer, but the methodology used both a capture antibody, covalently attached to a bead set, and a fluorescent detection antibody for each cytokine 14 . A simpler system for capturing a protein on a bead set consists of a tagged fusion protein and beads that bind the tag. A competitive screening assay can then be built by mixing (coating) the beads with the tagged protein, washing away excess protein and incubating the coated beads with a fluorescent binding partner in the absence or presence of small molecules: in the absence of inhibitors, the beads are bright; in the presence of inhibitors, the beads become dim. Successful multiplexing of two proteins demands two bead sets that have different optical signatures (e.g., if the binding partner has green fluorescence, the two bead sets might have different red fluorescence intensities). Each fusion protein is then mixed individually with a bead set, the coated beads are washed separately and mixed together with the green fluorescent binding partner, the suspension is gently mixed to allow the bead sets to approach equilibrium green fluorescence and the optical signals from the beads are measured with a flow cytometer. We have found that GST-tagged fusion protein performs well (see Experimental design section), although other epitope-tagging schemes such as avidin/biotin have also proven useful.
Screening applications
The GST fusion protein multiplex approach described here should be generally applicable for any family of proteins to which a GST tag can be added without disturbing the binding characteristics. The University of New Mexico Center for Molecular Discovery has completed screening of the National Institutes of Health (NIH) Molecular Libraries Small Molecule Repository, using this method. Data have been reported in PubMed for a series of small G-proteins binding a fluorescent GTP analog in addition to the screen described here. PubChem AID (assay identification) numbers are 757 (Rac), 758 (Rab7), 759 (Ras), 760 (Rab2), 761 (Cdc42) and 764 (Rac act). In addition to the fluorescent peptide described here, other screens could use other types of fluorescent compounds, for example, analogs of receptor ligands, nucleotides or nucleotide oligomers, sugars, lipids and GFP-tagged proteins. Hits in screening are retested in a dose-response assay, 32 of which can be performed on one 384-well plate, to confirm the activity of a hit.
For dose-response analysis, we have elected to obtain most of the possibly useful substructures or scaffolds in the library, and then use the dose-response series to eliminate false positives and place the confirmed compounds in an order of their potency. Following a single determination for each compound in the primary screen, compounds that were available were retested by a dose-response series. Table 1 shows the number of molecules that we defined as producing 40% inhibition with an EC 50 ≤ 10 µM. Active molecules were lost at this stage based on the hit criteria, fluorescent artifacts and molecules that interfered with the GSH to GST interaction. A 'counterscreen' has been deposited in PubChem (BioAssay AID 1324) with 19 compounds assessed as affecting the GSH to GST interaction. Moreover, in addition to using blank beads as control, experience suggests that a bead displaying an inactive protein in the multiplex family may provide additional information regarding compound fluorescence. A detailed analysis of this screen and follow-up is in process 15 .
Experimental design
Choice of fusion protein. During incubation, the tagged proteins must not dissociate significantly from the beads. We have investigated the six histidine, biotin and GST tags. Fortuitously, the GST tag shows very slow dissociation from GSH bead surfaces, possibly because of rebinding as well as dimerization of the GST moieties, thus making the GST tag a good choice for multiplexed screening 16, 17 .
Determining cutoff values for dose-response assays. Because the data were obtained in a multiplex format, any compound tested for a given protein was automatically tested on all six proteins, to determine which interactions exhibited an inhibition 40%, a K d ≤ 10 µM and an error of log K d 0.5. Importantly, although the assay data in PubChem were analyzed only for inhibitory hits, a number of compounds proved to show simultaneous inhibition of binding to one protein and augmentation of binding to another protein.
Compounds could thus be assigned different bioassay profiles, such as (i) selective inhibitors (inhibitor of Bfl-1 alone or in combination with others), (ii) selective activators and (iii) mixed activator and inhibitor (e.g., an inhibitor of Bfl-1 and an activator of Bcl-B).
Optimizing coating conditions. The multiplex GST fusion protein assembly described here depends on two binding constants for each fusion protein, one for the bead-borne GSH to the GST fusion protein and one for the fusion protein to the F-Bim. We have observed that while some fusion proteins bind to GSH beads adequately, they dissociate too rapidly for 1 h of incubation as used here and thus produce low fluorescence; incubation time can be adjusted to determine whether this observation is correct. If the incubation time is too short, however, the binding of the fluorescent probe may not reach equilibrium and produce suboptimal fluorescence. Thus, the incubation time and concentration must be optimized Bfl-1 hits were not included in the number of total hits because the dose-response results from the original Bfl-1 preparation were not replicated with a new preparation in the FP dose-response analysis; total hits equals the number of unique compounds affecting one or more of the other five anti-apoptotic Bcl-2 family members.
to obtain conditions that yield a maximal, stable signal. Some GST fusion proteins may show less reliable binding to the GSH beads. However, as many GST pull-down assays have been reported, it is probable that most GST fusion proteins will bind the beads well. We are fortunate that the K d values for the binding of F-Bim to the proteins cover a small range, from 6 to 60 nM (Fig. 3a) . The assay, using 50 nM F-Bim, has the potential to be more sensitive to inhibitors for some proteins than others (see Box 1).
Optimizing incubation conditions. Although GST fusion proteins are readily prepared by affinity purification, some differences in activity of the fusions will occur. The amount of each GST fusion protein used to coat the bead sets for 24 plates as described was 16, 40, 15, 25, 29 and 20 µg for Bcl-xL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1, respectively. Amounts are adjusted to yield uninhibited median fluorescence intensity (MFI) values of 100-400, corresponding to ~100,000-400,000 standard fluorophores per bead, which is convenient for screening purposes. Our proteins were stable for 3 d at 0-4 °C, but each system should be checked for stability.
Controls.
The NIH Molecular Libraries Small Molecule Repository is plated in 320 wells of 384-well plates to allow a pair of controls at each end of each row. We chose to use two negative controls on each row but just one determination a day for the positive control (an excess blocking concentration of nonfluorescent Bim) in order to save on the cost of Bim. One particular problem, fluid carryover of fluorescent compound from one well to the next, was addressed in part by using the seventh uncoated bead set to assist in identifying nonspecific fluorescence for a given well. The fluid carryover depends in part upon the length of the delivery tubing in HyperCyt 18 , and alternate delivery geometries are under exploration. Beads coated with inactive proteins from the multiplex family may serve as complementary controls.
Number of replicates required. As the beads are more homogeneous than cells, we have observed that z′ factors are typically better for bead-based assays than for cell-based assays. This assay routinely yields z′ factors of 0.69-0.82, which implies statistically meaningful results for a single point assay. If an assay yields lower z′ factors, more controls may need to be run, or replicates might be necessary. We then choose to define a hit at low stringency, accepting that the dose-response series will be done on many false positives, while ensuring that we will miss only a few true positive compounds.
Box 1 | ASSAY SENSITIVITY To TARGETS WITH DIFFERENT K D VALUES
Assuming that the bead fluorescence follows the formula of a simple binding curve, , a 40% loss. Thus, a hit for the 30 nM interaction could be set at 26% inhibition, whereas a hit for the 100 nM interaction could be set at 40% inhibition, to give a more comparable selection of inhibitory compounds than our 40% inhibition for all targets. If the range of K d values were larger for another multiplex, the multiplex could be divided into two multiplex assays, each spanning a smaller range of K d values. Allosterism is also possible.
MaterIals

REAGENTS
Test compounds: prepared as 10 − 3 M stocks in DMSO (Fisher, cat. no., D136-1) Buffer components: HEPES hemisodium salt (yields pH 7.5; Sigma, cat. no. H7637; Note: Sigma's formula weight is now based on the sodium, but we are interested in the concentration of HEPES); KCl (Sigma, cat. no. P4504); NaCl (Sigma, cat. no. S9625); MgCl 2 (Sigma, cat. no. M9272); Tween-20 (BioRad, cat. no. 170-6531); and BSA (Sigma, cat. no. A3059) Peptides (see REAGENT SETUP for solutions) Bim BH3 peptide (Abgent): CEIWIAQELRRIGDEFNAYYAR; ! cautIon verify peptide solubility. Fluorescent Bim BH3 peptide (Commonwealth Biotechnology, special synthesis): fluorescein isothiocyanate-6-aminohexanoic acid-DMRPEIWIAQELRRIGDEFNAYYAR Glutathione beads (GSH beads, Microgenics, now Thermo Fisher Scientific, special order. We bought 10 ml each of ten sets, each set with a different quantity of red fluorescent dye internal to the bead, producing ten intensities of red fluorescence.) Each polystyrene bead set (intensity of red fluorescence) is supplied at 1.4 × 10 5 beads µl − 1
. The beads have a diameter of ~4 microns, with ~1.2 million GSH sites per bead, determined as described earlier using GST-GFP 17 . The earlier work used dextran beads with a different method of GSH linkage, and a different assay buffer; we now obtain a K d of 10 nM for GST-GFP, using overnight coating at 4 °C. ). This kit contains five sets of beads, with a measured green fluorescence for each set in the fluorescein isothiocyanate, or fluorescein, channel, using a 488-nm laser for excitation and (in our instrument) a 530 ± 20-nm emission filter. The fluorescence is given in mean equivalents of soluble fluorophores ranging from 40,000 soluble fluorescein equivalents to 1,100,000 soluble fluorescein equivalents and is used to calibrate the instrument response daily. GST fusion protein aliquots, ~20 µg per frozen aliquot of 4 µl in buffer containing 10% (vol/vol) ethylene glycol, for 24 plates. These have been previously described 11 . ! cautIon Note the differences in peptide binding for Bcl-B in Figure 3a and b, which were done more than a year apart. Proteins should be checked for activity before the screen and before any follow-up assays.
EQUIPMENT
Assay plate (Greiner Bio-One, cat. no. 784101; 384 well, 30 µl maximum volume) Sealing covers for plates (GeneMate, cat. no. T-2417-6; we press-seal these with a roller) Microcentrifuge (Eppendorf, cat. no. 5417R; others will work) Rotating mixer (Fisher, cat. no. 14-059-346; plates are held on with rubber bands) Biomek • acquisition software must include a time parameter capable of binning data at 100-ms intervals continuously for 15 min or more. The cytometers that we have successfully used include a CyAn ADP (Dako, now Beckman-Coulter), an LSRII (Becton-Dickinson) and an Accuri C6 (Accuri). HyperCyt instrument (IntelliCyt) This instrument includes an autosampler, a peristaltic pump, 25-G stainless steel tube inlet probes, a Peltier cooling device for plates and PVC tubing. Software for HyperCyt The software, commercially available from IntelliCyt (http://www.intellicyt.com), includes two programs that are needed to run the HyperCyt platform: HyperCytSampler controls the autosampler, whereas HyperCytDataAnalysis is used to bin the time-resolved files stored in flow cytometry standard 2.0 or 3.0 formats, and then reduce and correlate the data file with compounds, as described later. HyperCyt setup This is set up as described earlier 2 . The cooling device replaces the supplied stand for holding the plate and should be raised to ensure that the plate occupies the same position for sampling as it would have on the supplied stand. proceDure  crItIcal step All steps are performed at 0-4 °C.
1|
Block the bead sets from nonspecific binding. For each of the seven GSH bead sets, pipette 340 µl of buffer (REAGENT SETUP) into a microcentrifuge tube and add 140 µl of the bead set. Mix the beads well, without foaming, and allow the BSA and Tween-20 (present in the buffer) to block nonspecific binding while the beads settle for 20 min. ? trouBlesHootInG 2| Coat the bead sets with GST-fusion proteins. Thaw aliquots of the six GST-fusion proteins and coat six of the seven blocked bead sets. Mix each blocked bead set (now 480 µl each) with its fusion protein (we used 4-µl aliquots of each protein) well, without bubbles, and let the seven separate suspensions settle on ice overnight. The seventh bead set remains uncoated and will serve as a scavenger for unbound GST-proteins, with associated fluorescence, during the assay. The amount of each GST-fusion protein in the 4-µl aliquot used to coat the bead sets for 24 plates as described was 16, 40, 15, 25, 29 and 20 µg for Bcl-xL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1, respectively. Amounts of fusion proteins were adjusted to yield specific MFI values of 100-400, corresponding to ~100,000-400,000 standard fluorophores per bead based on comparison with the Bangs Labs standard beads, which is convenient for screening purposes.  crItIcal step It is common practice to keep the beads suspended during coating, but one of our fusion proteins (GST-Mcl-1) lost ~50% of its binding activity while rotating end-over-end gently overnight with no bubbles formed, and another one (GST-Bcl-2) produced clumped beads. All of the proteins showed good binding and no bead clumping with overnight settling, so we let them settle. Test your system for the best coating conditions.  pause poInt The protocol can be paused at this point for as long as the proteins remain stable.
3|
Mix to resuspend the beads, pipette 75 µl of each coated bead set into a fresh microcentrifuge tube and pellet the bead sets separately at 6,000g for 2 min. Remove the supernatants and resuspend all the beads together in 200 µl of buffer. This is enough for four 384-well plates.
4|
Pellet the mixture by centrifugation as above, remove the supernatant, resuspend the beads in 8.5 ml of buffer and transfer them to a cold trough/reservoir for distribution to an assay plate by the Biomek FX P .
5|
Program the Beckman-Coulter Biomek FX P robot to deliver 5 µl of bead suspension, 0.1 µl of compound or control in DMSO (using the pin tool device) and 5 µl of 100 nM F-Bim to each well, and then mix them. Use the eight-tip pod to deliver the coated beads from a cold trough, which is slow but not wasteful of the expensive reagent; use the 384-tip pod for the addition of F-Bim and for mixing. Columns 23 and 24 on the plate have no beads added. This results in a temporal gap in data acquisition at the end of each row that facilitates accurate identification of rows and wells within rows during post-acquisition data analysis.
6|
Cover and rotate the plate end-over-end slowly to maintain suspension at 4 °C for 1 h. For our fusion proteins, the competitive data remain very similar between 1 and 3 h. Our system rotates the plate at 10 r.p.m.  pause poInt The pause can be as long as your assay output remains stable. ? trouBlesHootInG 7| Adjust the voltage/gain of the photomultiplier tube for the fluorescein channel (488 nm excitation, 530 ± 20 nm emission) such that the MFI reads 100 when the standard beads with 100,000 mean equivalents of standard fluorophores are applied, and adjust the voltage/gain of the photomultiplier tube for the red channel (635 nm excitation, 665 ± 10 nm emission) so that the bead sets are well separated. ? trouBlesHootInG 8| Move the plate to the plate cooler on the HyperCyt autosampler deck for high-throughput sampling and flow cytometric measurements. Fill the sample tubing with 50 nM F-Bim and allow it to coat the interior tubing wall for 20 s just before the plate run.
9|
Start the plate run. The autosampler moves from well to well under the control of HyperCytSampler software, sampling for 1 s from each well and pausing 0.4 s in air before sampling the next well. The series of 384 bubble-separated samples is delivered to the flow cytometer and is measured as a single data file that is saved in flow cytometry standard 2.0 or 3.0 formats, typically ~10 megabytes per file. Our numbers of beads and sampling times result in more than 200 beads of each type per well on average, and we consider fewer than 50 beads of a given set to be inadequate. If this occurs, the plate can be mixed again and run with a 50% longer sample sip time for each well. ? trouBlesHootInG 10| Open a data file with HyperCytDataAnalysis software and gate the bead sets. The gates are drawn manually. In a twoparameter dot plot of forward scatter versus side scatter (in which each bead is rendered as a dot) for a plate, gate the singlet beads as shown in Figure 1b ; doublet beads are the dark blue dots on this dot plot with slightly higher forward scatter and side scatter. ? trouBlesHootInG 11| Select to display only the beads inside the gate, and in a two-parameter plot of log side scatter versus log red fluorescence intensity (FL8, 635 nm laser, 665 ± 10 nm emission), make a second gate around all the bead sets as shown in Figure 1c , gate 2. This allows all the bead sets to be displayed as a density map during subsequent gating.
12|
Gate the individual bead sets as shown in Figure 1c (the gates for the first plate remain good for the other 23 plates that day) and identify time bins. As we have chosen to let columns 23 and 24 of a 384-well plate have no beads, we have only 352 wells to bin. HyperCytDataAnalysis software is then used to identify 352 time bins, which are all displayed in a window in ~3 s as shown in Figure 2a : this plots events (beads per 0.1 s) versus time; the time bins must be repartitioned and reanalyzed for each plate. Each time bin corresponds to a well. An expanded display of data is provided to check for errors in time binning, and to redraw the bins if necessary. We show Row B as an example (Fig. 2b) . Note the low bead carryover observed when the two bead-free wells (not binned) at the end of each row were sampled. We have included the complete analysis file for this plate as supplementary Data 1.
13| Generate a reduced data file using HyperCytDataAnalysis software. It is instructive to view part of Row B with log FL1 (green fluorescence intensity) on the y axis (Fig. 2c) . For this plate, it appears to the eye that three proteins had an MFI near 400, three an MFI near 200 and the GSH (or scavenger) beads an MFI near 20. It also appears that in bin B5, beads from some set(s) have less fluorescence. The program then calculates the number of beads and the MFI for each bead set in every time bin and displays these data in tabular form.
14|
Correlate these data with the compound list used for that plate, and export the correlation to a Microsoft Excel spreadsheet as a comma-separated values (.csv) file. The MFI values for wells B3-B7 (Fig. 2d) show that the compound in well B5 apparently inhibited F-Bim binding to Bcl-B more than 50% and did not inhibit the other proteins significantly, thus suggesting specificity for one protein target for this inhibitor. This reduced data file is typically 42 kilobytes for a plate.
15|
Calculate the assay responses and quality statistics using the equations given earlier, which described another competitive binding assay Change the probe and tubing. Each day, rinse the system for 20 min with buffer containing detergent. Large clumps of beads or cells will sporadically break off and be recorded by the cytometer, but the frequency and size of these will decrease. A sign of back-pressure on the flow stream is that the air gaps between slugs of beads in the peristaltic pump tubing are much shorter (i.e., more compressed) on the cytometer side of the pump than on the plate side of the pump. Clumps of particles can also accumulate on the larger diameter plastic tubing as it leaves the short steel connector tube to enter the cytometer. Removing the steel connector should allow the pressurized cytometer sheath fluid to back out of the plastic tubing, and if it is still clogged, cut off 1 cm of tubing to obtain flow, and then reconnect HyperCyt
There is a Biomek error in pipetting
Load the plate again. This is quite uncommon with proper daily maintenance • tIMInG Although a single person has performed this assay in our laboratory, we assume two people working together with one person loading reagents into the plates and analyzing the data, and the other person running HyperCyt and the cytometer as follows:
Step 1, 30 min, once per day
Step 2, 1-42 h; overnight is convenient, once per day (it can be prolonged to 42 h for our proteins)
Step 3, 20 min
Step 4, 10 min
Step 5, 2 min, once per day for program; 5 min per plate for loading
Step 6, 1 h for our approach to equilibrium; other assays may differ (it can be extended to 3 h for our proteins)
Step 7, 15 min, once per day
Step 8, 2 min per plate
Step 9, 12 min per plate
Step 10, 30 s, once per day
Step 11, 30 s, once per day
Step 12, 2 min, once a day to draw the gates; 2 min per plate for binning and checking bins
Step 13, 30 s per plate
Step 14, 20 s per plate
Step 15, 30 s per plate We run ≥40 plates per day, with two people working, and have achieved over 100 plates per day with four people working in shifts using four flow cytometers.
antIcIpateD results
The purpose of a screen is to identify molecules that will enhance or diminish the interactions between biological molecules in a cost-effective manner. In the literature, an assay describing the binding between any two entities will be found to differ with respect to time, temperature, ionic conditions and source of materials from different laboratories.
The basic conditions to be met for a screen are (i) a binding curve that reproduces a K d that was found by others, and (ii) a competition dose-response series using a known competitor that reproduces an EC 50 value that was found by others, with due respect for nonspecific binding; both these criteria were met in this protocol (Fig. 3) .
There is a potential for the screened compounds to inhibit the GSH to GST interaction, and compounds that yield an identical dose-response curve for all six proteins are checked. If the compound inhibits the binding of 2 nM GST-GFP to uncoated beads, the data are inconclusive and the competitor is flagged as a potential GSH to GST inhibitor and/or as a possibly promiscuous protein binder (i.e., a false positive). For this determination, 2 nM GST-GFP should be incubated overnight with the beads as in Step 2, yielding beads that are coated with GST-GFP. Furthermore, the assay can be carried out with and without addition of suspect compounds. We recognize as active compounds (compounds that have activity in the assay and no significant activity in counterscreen assays, and that do not involve GST-GFP interactions as an assay component) only those molecules that weakly interfere (based on magnitude and affinity) with GST-GFP fluorescence compared with the target F-Bim fluorescence.
During assay development with relatively few beads, the loss of beads due to adsorption on pipette tips and tube walls can become overwhelming (e.g., expecting 20,000 beads in a well, yet counting only 200 at the cytometer). We suggest the use of 0.01-0.1% detergent in the buffer to minimize adsorptive losses. Our 'blocking' of the beads in Step 1 contributes to this function, among others.
In summary, we believe that this assay gives results comparable to the more commonly used fluorescence polarization and TR-FRET methods, with the advantage of the ability to multiplex data from a series of protein targets, including uncoated GSH beads as a measure of control for nonspecific fluorescence due to fluorescent compound adsorption.
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